„D-dimerosis” among the patients with the cancer it is always needed to be treated?
Journal Title: OncoReview - Year 2012, Vol 2, Issue 2
Abstract
The risk of thromboembolic disease increases in malignant tumors. D-dimer is a product of fibrin degradation. Its concentration rises in neoplasms, but also in another diseases characterized by activation of clotting and fibrinolysis, and therefore has low specificity. Elevated level of D-dimer gives a low positive predictive value to confirm thromboembolic disease and should not be used to confirm it. However its high negative predictive value allows reliable exclusion of thromboembolic disease provided pretest clinical probability is taken into account. In clinical practice D-dimer has to be measured by a sensitive tests, and the immunoenzymatic tests (VIDAS) seem to be the best in oncology. D-dimers can be useful to assess the risk of thromboembolic event recurrence after stopping anticoagulation. Additionally it can be used for the diagnosis of disseminant intravascular coagulation and as a marker of malignant tumor progression or reccurence.
Authors and Affiliations
Maria Wieteska, Michał Florczyk, Adam Torbicki
Keywords
Related Articles
- EP ID EP53156
- DOI -
- Views 221
- Downloads 0
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
Multiple myeloma. Practical aspects regarding diagnosis and treatment
Practical aspects of multiple myeloma diagnosis and treatment has been discussed. Myeloma diagnosis should be supported with immunoglobulin’s isotype and serum free light chain immunoglobulins studies. It is particularly...
Invasive fungal infection in a child with Ewing’s sarcoma
Invasive fungal infection (IFI) in patients with malignant solid tumours is rare, but it highly increases the risk of cancer recurrence because of prolonged discontinuation of cancer treatment. This paper presents a case...
Większa skuteczność nilotynibu niż imatynibu w leczeniu przewlekłej białaczki szpikowej w fazie przewlekłej. Analiza aktualnych wyników badania ENESTnd i ENESTcmr
Inhibitory kinaz tyrozynowych II generacji jako pierwszy wybór w przewlekłej białaczce szpikowej (CML) w fazie przewlekłej zwiększają skuteczność terapii i poprawiają rokowanie. Pierwotnym celem badania ENESTnd było poró...
Cardiac amyloidosis: a hidden cause of cardiovascular complications in oncology practice
Amyloidosis is rare, but known cause of heart failure, cardiomyopathy, coronary artery disease, disorders of cardiac conduction system and valvular damage. Disease often remains undetected until it reaches an advanced st...